These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 11521803)

  • 1. Anthracycline-induced acute cardiotoxicity in adults treated for leukaemia. Analysis of the clinico-pathological aspects of documented acute anthracycline-induced cardiotoxicity in patients treated for acute leukaemia at the University Hospital of Zürich, Switzerland, between 1990 and 1996.
    Dazzi H; Kaufmann K; Follath F
    Ann Oncol; 2001 Jul; 12(7):963-6. PubMed ID: 11521803
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiac toxicity after anthracycline chemotherapy in childhood.
    Iarussi D; Indolfi P; Galderisi M; Bossone E
    Herz; 2000 Nov; 25(7):676-88. PubMed ID: 11141677
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Medical interventions for treating anthracycline-induced symptomatic and asymptomatic cardiotoxicity during and after treatment for childhood cancer.
    Sieswerda E; van Dalen EC; Postma A; Cheuk DK; Caron HN; Kremer LC
    Cochrane Database Syst Rev; 2011 Sep; (9):CD008011. PubMed ID: 21901716
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anthracycline-related acute cardiotoxicity in a very young Omani patient with acute myeloid leukaemia.
    Tony S; Mevada R; Joshi N
    Cardiol Young; 2021 Mar; 31(3):464-467. PubMed ID: 33228820
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of cardiomyopathy in acute myeloid leukemia patients treated with anthracyclines.
    Mort MK; Sen JM; Morris AL; DeGregory KA; McLoughlin EM; Mort JF; Dunn SP; Abuannadi M; Keng MK
    J Oncol Pharm Pract; 2020 Apr; 26(3):680-687. PubMed ID: 31500517
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardioprotection against the toxic effects of anthracyclines given to children with cancer: a systematic review.
    Bryant J; Picot J; Levitt G; Sullivan I; Baxter L; Clegg A
    Health Technol Assess; 2007 Jul; 11(27):iii, ix-x, 1-84. PubMed ID: 17610809
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anthracycline-induced cardiotoxicity: clinical course, risk factors, pathogenesis, detection and prevention--review of the literature.
    Wojtacki J; Lewicka-Nowak E; Leśniewski-Kmak K
    Med Sci Monit; 2000; 6(2):411-20. PubMed ID: 11208348
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Cardiotoxicity of anthracyclines].
    Costache II; Petriş A
    Rev Med Chir Soc Med Nat Iasi; 2011; 115(4):1200-7. PubMed ID: 22276470
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influencing factors of anthracycline-induced subclinical cardiotoxicity in acute leukemia patients.
    Zhou X; Weng Y; Jiang T; Ou W; Zhang N; Dong Q; Tang X
    BMC Cancer; 2023 Oct; 23(1):976. PubMed ID: 37833648
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anthracycline-induced cardiotoxicity in children with malignancies.
    Godoy LY; Fukushige J; Igarashi H; Matsuzaki A; Ueda K
    Acta Paediatr Jpn; 1997 Apr; 39(2):188-93. PubMed ID: 9141252
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exposure to anthracyclines during childhood causes cardiac injury.
    Lipshultz SE
    Semin Oncol; 2006 Jun; 33(3 Suppl 8):S8-14. PubMed ID: 16781284
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Different dosage schedules for reducing cardiotoxicity in cancer patients receiving anthracycline chemotherapy.
    van Dalen EC; van der Pal HJ; Caron HN; Kremer LC
    Cochrane Database Syst Rev; 2006 Oct; (4):CD005008. PubMed ID: 17054232
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Late anthracycline cardiotoxicity protection by dexrazoxane (ICRF-187) in pediatric patients: echocardiographic follow-up.
    Elbl L; Hrstkova H; Tomaskova I; Michalek J
    Support Care Cancer; 2006 Feb; 14(2):128-36. PubMed ID: 16034614
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pathophysiology and preventive strategies of anthracycline-induced cardiotoxicity.
    Chung WB; Youn HJ
    Korean J Intern Med; 2016 Jul; 31(4):625-33. PubMed ID: 27378126
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Cardiotoxicity of daunorubicin and aclacinomycin A in patients with acute leukemia].
    Haruyama H; Shimazaki C; Nakanishi S; Hamami T; Nisio A; Isemura T; Katsume H; Nakagawa M; Ijichi H
    Gan To Kagaku Ryoho; 1982 Mar; 9(3):516-21. PubMed ID: 6964037
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence and predictors of anthracycline cardiotoxicity in children treated for acute myeloid leukaemia: retrospective cohort study in a single centre in the United Kingdom.
    Temming P; Qureshi A; Hardt J; Leiper AD; Levitt G; Ancliff PJ; Webb DK
    Pediatr Blood Cancer; 2011 Apr; 56(4):625-30. PubMed ID: 21298750
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anthracycline-induced cardiotoxicity in children with cancer: strategies for prevention and management.
    Iarussi D; Indolfi P; Casale F; Martino V; Di Tullio MT; Calabrò R
    Paediatr Drugs; 2005; 7(2):67-76. PubMed ID: 15871628
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Different anthracycline derivates for reducing cardiotoxicity in cancer patients.
    van Dalen EC; Michiels EM; Caron HN; Kremer LC
    Cochrane Database Syst Rev; 2006 Oct; (4):CD005006. PubMed ID: 17054231
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Detection of anthracycline-induced cardiotoxicity: is there light at the end of the tunnel?
    Suter TM; Meier B
    Ann Oncol; 2002 May; 13(5):647-9. PubMed ID: 12075731
    [No Abstract]   [Full Text] [Related]  

  • 20. Brain natriuretic peptide is a predictor of anthracycline-induced cardiotoxicity.
    Okumura H; Iuchi K; Yoshida T; Nakamura S; Takeshima M; Takamatsu H; Ikeno A; Usuda K; Ishikawa T; Ohtake S; Matsuda T
    Acta Haematol; 2000; 104(4):158-63. PubMed ID: 11279304
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.